Comparative Pharmacology
Head-to-head clinical analysis: ORENITRAM versus VENTAVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORENITRAM versus VENTAVIS.
ORENITRAM vs VENTAVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ORENITRAM (treprostinil) is a prostacyclin analog that directly vasodilates pulmonary and systemic arteries, inhibits platelet aggregation, and reduces pulmonary vascular resistance via IP receptor activation, increasing cAMP levels.
Ventavis (iloprost) is a synthetic prostacyclin analog that causes vasodilation by increasing cyclic adenosine monophosphate (cAMP) levels in vascular smooth muscle cells, leading to relaxation and inhibition of platelet aggregation.
Initial: 0.125 mg orally twice daily; titrate as tolerated in increments of 0.125 mg twice daily every 2 weeks. Maximum dose: 1.5 mg twice daily.
Inhaled: 2.5 mcg or 5 mcg via I-neb AAD system, 6 to 9 times daily (maximum 45 mcg/day). Titrate based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with pulmonary arterial hypertension (PAH). Clinical context: Requires twice-daily dosing or continuous IV infusion to maintain therapeutic concentrations.
Terminal elimination half-life: 0.45–1.0 hour (intravenous). Short half-life necessitates continuous intravenous or frequent nebulized administration for sustained effect.
Approximately 50-70% as unchanged drug and 10-15% as inactive metabolites via urine; 4-14% via feces (biliary/fecal route) as unchanged drug and metabolites. Total renal clearance accounts for ~50% of total clearance.
Renal: ~6% as unchanged drug; biliary/fecal: minimal; extensive hepatic metabolism with metabolites primarily excreted in urine (50-60% of total clearance). No significant renal or biliary excretion of parent drug.
Category C
Category C
Prostacyclin Analog
Prostacyclin Analog